Pharmicell CEO Hyunsoo Kim Purchases Company Shares, Demonstrates Firm Commitment to Responsible Management

Pharmicell announced on January 28 that CEO Hyunsoo Kim purchased 14,000 shares of the company through on-market transactions.

This share buyback demonstrates the CEO's strong confidence in the company's mid- to long-term growth directly to the market as both the largest shareholder and chief executive officer, while also conveying a firm commitment to enhancing shareholder value through responsible management.

Pharmicell continues its rapid growth, driven by strong performance in its biochemical business division. In fact, the company set a new record for cumulative performance in the third quarter of last year, proving the robustness of its fundamentals.

Additionally, the company is accelerating the diversification of its business portfolio, which spans advanced regenerative medicine and AI materials, by achieving visible results in the electronic materials sector, particularly with low-dielectric materials.

A Pharmicell representative stated, "Despite our solid performance and business growth, we believe the current share price is excessively undervalued compared to the company's intrinsic value. This share buyback marks the official starting point for responsible management and the enhancement of shareholder value. We will do our utmost to ensure that the company's future growth leads to a revaluation of our corporate value."

This content was produced with the assistance of AI translation services.